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Abstract The association of chronic migraine (CM) with
an idiopathic intracranial hypertension without papille-
dema (IIHWOP), although much more prevalent than
expected in clinical series of CM sufferers, is not included
among the risk factors for migraine progression. We dis-
cuss the available evidence supporting the existence of a
pathogenetic link between CM and idiopathic intracranial
hypertensive disorders and suggest a causative role for
IIHWOP in migraine progression.
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Progression of migraine
Convergent clinical, functional and anatomical evidences
indicate that migraine can progressively worsen leading to
an almost daily condition [1–6]. Chronic migraine (CM)
taxonomy has evolved in recent years. The current ICHD-II
criteria for CM [7] have resulted unpractical because of
their low sensitivity [8]. The new appendix criteria for CM
issued in 2006 (ICDH-II R CM) [9] have proven to be as
sensitive [10–12] as those proposed for transformed
migraine (TM), a subtype of chronic daily headache
(CDH), by Silberstein and Lipton [13]. The use of appen-
dix criteria for CM has been strongly recommended to
allow its extensive field testing considering a possible
inclusion into the next classification revision. Still, in the
present review we will refer also to clinical and epidemi-
ological papers published before the release of appendix
criteria of 2006. In such cases, we will use the terms CDH,
TM, ICDH-II CM; according to the actual criteria set
chosen by the authors for patients selection.
Population prevalence of TM with or without medi-
cation overuse is about 1–2% [14]. Therefore, this con-
dition is emerging as a dramatic worldwide health
problem, with a deep impact on both direct and indirect
social costs [15–17]. Chronification of migraine is char-
acterized by a progressive increase in headache frequency
and duration, often parallel to the reduction in pain
intensity and accompanying symptoms. The process goes
on over months or years, ultimately leading to a contin-
uous mild pain with superimposed exacerbations of
moderate to severe migrainous pain. Several evidences
support such an evolution [3–6].
A longitudinal survey [5] has shown that infrequent
episodic headache sufferers (2–104 days per year) carry a
6% annual risk to progress to a frequent episodic pattern
(105–179 days per year) and a 3% annual risk to develop a
chronic condition. In the same study, a spontaneous return
to a frequent or infrequent episodic pattern (\180 days per
year) was observed in 57% and to \1 attack per week in
14% of chronic sufferers. These data suggest that some
migraine patients are at a risk for a progressive headache
worsening and that progression of migraine is a clinically
dynamic and reversible event. These observations highlight
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the need for a prompt identification of population at a risk
and of factors associated with both the progression of
migraine and the possible return to an episodic pattern.
Factors involved in migraine progression: focus
on medication overuse
Non-modifiable risk factors associated with the progres-
sive worsening of migraine include age, female sex, white
race, low educational level, socioeconomic status and
genetic factors. Among modifiable risk factors that
include frequent migraine attacks, obesity, excessive use
of acute medications, sleep disorders, caffeine overuse,
stressful life events, depression and cutaneous allodynia
[18, 19], medication overuse is the best known and the
more investigated. Because discontinuation of overuse
alone is followed by the return to an episodic pattern
in about half of the patients [20], or by the restoration
of responsiveness to prophylactic treatments in many of
the non-responders [21], medication overuse headache
(MOH) is recognized as causative factor for migraine
progression. Consequently, it is classified as an autono-
mous entity among the secondary headaches. The new
appendix criteria for MOH [9] eliminated the need for a
return to an episodic pattern after a 2 months overuse
discontinuation, so that a definite diagnosis can now be
reached already at the first visit.
Interestingly, MOH only occurs in subjects with a
previously episodic primary headache. Among 103
patients presenting to a rheumatology-monitoring clinic
with a daily use of analgesics, 8 subjects (7.6%) devel-
oped a chronic headache and all of them had a previous
episodic migraine [22]. However, episodic migraine
prevalence in the rheumatologic patients who did not
develop a chronic headache after a prolonged daily use of
analgesics was much higher (40%), indicating that not all
migraine subjects exposed to medication overuse actually
progress towards a chronic form. On the other hand,
according to existing population data, up to two-third [23,
24] of chronic headache sufferers do not overuse acute
medications. Primary headaches progression sustained by
medication overuse is not limited to migraine, but
extended to the whole CDH spectrum [25]. This is in
agreement with the medication overuse putative mecha-
nism of action, attributed to a reversible central sensiti-
sation of pain processing pathways mainly involving the
thalamocortical level [26].
Thus, medication overuse remains the more common
and the best-known factor associated with the chronic
transformation of pain in episodic migraine subjects but it
cannot be easily considered neither a sufficient nor a nec-
essary factor for migraine progression.
Idiopathic intracranial hypertension (IIH)
with and without papilledema
Idiopathic intracranial hypertension [27] is an infrequent
and enigmatic condition almost always encountered in
overweight or obese women of childbearing age. IIH is
characterized by headache, often on a daily basis, papil-
ledema, transient visual obscuration, diplopia and tinnitus.
Symptoms arise from a hypertensive intracranial status
which is not associated with any detectable cause. IIH may
run without papilledema (IIHWOP) in some patients [28,
29], but its prevalence on general population is not known.
Stenosis of large intracranial venous sinuses can be
found at magnetic resonance venography in almost all
affected subjects and is considered as a reliable radiologic
marker of intracranial hypertension with a high specificity
(93%) and sensitivity (93%) [30]. There is evidence [31] of
a venous pressure gradient across the stenosis with a
potential effect in increasing the cerebrospinal fluid (CSF)
pressure [32]. Conversely, the venous pressure gradient
normalizes soon after sub occipital CSF subtraction [31]
and the stenosis may reduce or resolve after a single 20-ml
CSF subtraction with lumbar puncture [33] or after con-
tinuous CSF diversion procedures, such as lumboperitoneal
shunt [34, 35]. These findings suggest that venous flow
disturbances in IIH are more probably the effect of CSF
hypertension, not its cause [36]. However, the placing of a
self-expanding stent at the venous stenosis level is fol-
lowed by the immediate and longstanding resolution of
symptoms in most of the cases [37]. Thus, on one hand, an
acute or continuous CSF subtraction may reduce the ste-
nosis degree; on the other hand, the stenting of segmental
venous narrowing at transverse sinus level may revert the
CSF hypertensive status. Taken together, these findings
indicate that, in IIH patients, sinus venous stenosis and
CSF hypertension may influence each other in a circular
way whose starting point may only arbitrarily be indicated.
Since the CSF pressure is higher than central venous
pressure (at least in clinostatic position), if a large central
vein were not sufficiently rigid then it would be com-
pressed as a consequence of transmural pressure gradient.
Consequently, it can be speculated that in subjects har-
boring one ore more collapsible segments of central veins
and exposed to an unknown CSF raising factor, the sub-
sequent segmental venous narrowing and the related fur-
ther CSF pressure rising may engage a positive feedback
loop. This loop is self-limiting: once the maximum
stretching of the venous wall is reached no further venous
narrowing could parallel CSF pressure rising, leading to a
relatively stable new balance at higher values of CSF and
venous blood pressures [33]. The hypothesis of a causative
‘‘self-limiting venous collapse’’ in IIH pathogenesis that we
proposed on the basis of clinical observations [33] is
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supported by a series of independent and about simulta-
neous mathematic modeling studies [38, 39]. In subjects
carrying one or more collapsible segment of large central
venous collectors, the hypothesis of a self-limiting venous
collapse may account at least for the maintenance of a
hypertensive intracranial status induced by a different
cause. It also gives full explanation of the relatively good
prognosis of ‘‘benign’’ intracranial hypertension as com-
pared to cerebral venous thrombosis, in which a venous
hypertension is sustained by an endoluminal obstruction, a
mechanism lacking any self-limiting property. Moreover,
the proposed mechanism may explain the not infrequent
long-term remissions observed in IIH patients after single or
serial CSF subtraction by LP. In fact, the acute subtraction
of even a small CSF volume, could account for a venous
expansion that may in turn reduce CSF pressure, ultimately
leading to the restoration of the previous relatively stable
balance at physiologic CSF and venous pressure values.
In contrast, there is evidence of the persistence of the
sinus venous stenosis at the RM venography in a small
series of IIH/IIHWOP patients exhibiting a normalized
intracranial pressure at follow-up while on medical treat-
ment (acetazolamide and weight loss) [40]. However,
according to the findings of an intracranial pressure mon-
itoring study on 10 IIHWOP subjects presenting with a
CDH [41], the CSF pressure may exhibit intraday, high
amplitude, pulsatile course in such patients. While the
opening pressure was found within normal limits in half of
the cases and the mean resting CSF pressure (recorded
along a 2–3 days of continuous CSF pressure monitoring)
was only 118 ± 17 mm H2O, slow waves of pathologically
high CSF pressures (mean peak = 560 mm H20) could be
recorded in all patients, mainly at night. All cases in this
series reported a dramatic improvement after shunt surgery.
Thus, a single LP may fail to identify the possible persis-
tence of CSF hypertension. Consequently, the finding of
stenosis persistence in subjects with normalization of CSF
pressure documented by a single LP does not argue against
the possible role of venous flow disturbances in IIH
pathogenesis.
Based on the reported observation, it can be hypothe-
sized that in subjects harboring one ore more collapsible
segments of central veins a ‘‘self-limiting venous collapse’’
may promote the development of a relatively stable CSF
hypertension status, ultimately leading to the clinical pic-
ture of IIH with or without papilledema.
Is IIHWOP pathogenetically involved in progression
of migraine?
Clinical presentation of IIHWOP may be limited to a mild
to moderate continuous headache, thus resembling a
chronic tension-type headache [42]. However, in most
cases, superimposed recurrences of severe migrainous pain
are reported, leading to a picture indistinguishable from
that of TM [43]. According to the results of the first sys-
tematic study on the coexistence of IIHWOP in chronic
headache sufferers [44] obesity and pulsatile tinnitus pre-
dicted the CSF hypertension while the headache profiles of
CDH patients with IIHWOP did not differ from that of
chronic headache sufferers without evidence of raised CSF
pressure. As a consequence, IIHWOP is frequently mis-
diagnosed as TM/CM. In a clinical series of 85 TM patients
diagnosed with chronic migrainous headache, Mathew
et al. [43] found a 14% prevalence of IIHWOP. More
recently, an IIHWOP has been diagnosed in 10% of 62 CM
patients (diagnosed with either ICHD-II or ICDH-II R
criteria for CM) referring to a Headache Centre [45]. In this
paper, the MR venography of the subgroup with IIHWOP
was reported as ‘‘normal’’ in all cases. This raised a criti-
cism to the paper in which the possible use of a suboptimal
imaging technique was hypothesized [46]. In their replay,
the authors admitted that bilateral venous abnormalities
were actually present in their series, but also in patients
without IIHWOP. Unfortunately, they did not provide the
prevalence data of the venous changes in the two groups.
There is evidence that, in migraine patients, sinus venous
stenosis predicts the presence of IIHWOP [47]. Unex-
pectedly, all migraine patients carrying bilateral transverse
sinus stenosis in this series were episodic, a finding
attributed by the authors to different methods to select
patients for the diagnostic LP. IIH and CM share some
relevant risk factors as: female gender, obesity and sleep
disturbances [18, 48, 49]. Topiramate a drug with growing
evidences of efficacy in CM [50, 51] shares with aceta-
zolamide the inhibition of carbonic anhydrase isoenzyme
[52]. Acetazolamide reduces intracranial hypertension and
is widely used in IIH treatment [53]. Topiramate has been
found effective in IIH treatment [54–56]. In a recent study,
topiramate resulted as effective as acetazolamide in IIH
treatment [56] suggesting that the efficacy shown by this
drug in CM treatment could be related, at least partially, by
an acetazolamide-like CSF pressure lowering effect.
IIH may occur without headache in non-migrainous
individuals or in the course of a well-known migraine
protective factor as pregnancy [57] suggesting that a
CM-like clinical presentation of IIHWOP could require a
migrainous predisposition. Thus, it can be speculated that,
in non-migrainous subjects, IIHWOP may be associated
with a mild to moderate tension-type pain, or may even run
un-associated to any symptom or sign. This consideration
rises the question of a possible relevant underestimation of
IIHWOP prevalence in general population.
The reported observations suggest a pathogenetic link
between IIH with or without papilledema and migraine
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(and, possibly, other primary headaches). At least in some
patients, the co-morbidity between IIH and migraine sig-
nificantly increases the clinical complexity of the syndrome
[58] and may promote the isolated worsening of headache
frequency and duration, ultimately leading to a CM-like
clinical picture. A similar mechanism could be involved in
the progression of other primary headaches, namely, of
chronic tension-type headache. Analogously to MOH, the
pain progression linked to IIH could require a primary
headache background.
Putative pathogenetic link between IIHWOP
and migraine progression
Putative mechanisms linking IIH and migraine progression
could involve a raised central venous pressure above the
sinus venous stenosis. Congestion of large venous sinuses,
most probably due to its high nociceptive innervation, may
aggravate a running migrainous pain [59, 60]. Thus, it can
be speculated that, in individuals carrying this co-morbid-
ity, a mild but persistent central venous hypertension could
promote a continuous nociceptive firing, leading to the
sensitisation of pain processing pathways and ultimately to
the progressive increase of attacks frequency and duration.
Conclusions
A number of evidences suggest that in migraine subjects
carrying one or more collapsible segment of central venous
sinus, the development of a co-morbid IIHWOP could
represent an important risk factor for the progression of
migraine. Since IIHWOP is not routinely excluded in
diagnostic work up for chronic headache, its co-morbidity
in migrainous patients is probably underdiagnosed (and
undertreated). A similar mechanism could be involved in
progression of pain in other primary headaches. We sug-
gest that IIHWOP should be suspected in every CM
patients with evidence of venous flow disturbances at MR
venography. Studies addressing the IIHWOP prevalence in
general population and in CM sufferers with or without
medication overuse are urgently needed.
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